{"article_id": "KMB_q4_2020.txt", "article": ["full year net sales were $ 19.1 billion .", "that 's up 4 % year - on - year and included a 2 point drag from currency rates .", "organic sales grew 6 % , with healthy underlying performance and increased demand related to covid - 19 .", "volumes were up 4 % , and net selling prices and product mix each increased 1 % .", "full year adjusted gross margin was 37.1 % , up 210 basis points year - on - year .", "adjusted gross profit increased 10 % .", "we generated $ 575 million of cost savings from our force and restructuring programs .", "for 2021 , we 're targeting $ 400 million to $ 460 million in total cost savings .", "commodities were favorable by $ 175 million in 2020 although they turned inflationary in the fourth quarter .", "we 're planning for commodity inflation of $ 450 million to $ 600 million in 2021 .", "moving further down the p&l , between the line spending was up 110 basis points as a percent of sales .", "that was driven by advertising , which was up 90 basis points .", "adjusted operating margin was 18.7 % , up 90 basis points , and adjusted operating profit grew 9 % .", "in terms of company profitability for 2021 , the midpoint of our planning assumptions implies a 70 basis point decline in adjusted operating margin .", "full year adjusted earnings per share were $ 7.74 , up 12 % .", "our october guidance was for earnings of $ 7.50 to $ 7.65 .", "now let 's turn to cash flow [ technical issues ] cash provided by operations was an all - time record $ 3.7 billion , up $ 1 billion year - on - year , reflecting outstanding working capital performance and strong earnings .", "capital spending was $ 1.2 billion in 2020 , in line with plan and the prior year .", "we plan to spend between $ 1.2 billion and $ 1.3 billion in 2021 , including activity for our restructuring program and a pickup in growth projects .", "on capital allocation , dividends and share repurchases totaled $ 2.15 billion .", "that 's the 10th consecutive year we 've returned at least $ 2 billion to shareholders .", "we 're about 85 % to 90 % through the total pre-tax charges , which we 've increased somewhat to reflect delays as a result of covid - 19 and costs for additional savings opportunities .", "so far , we 've generated $ 420 million of savings and expect to achieve between $ 540 million and $ 560 million of savings by the end of 2021 .", "our original savings estimate was $ 500 million to $ 550 million .", "finally , at this point cash payments are about 75 % to 80 % complete .", "looking more closely at our business segments , we saw excellent performance in personal care , with 5 % organic sales growth and strong share performance .", "in north america , organic sales rose 6 % , driven by broad - based growth in baby and child care .", "in d&e markets , personal care organic sales were also up 6 % despite volatile market conditions .", "organic sales were up 13 % in consumer tissue and down 7 % in k - c professional .", "importantly , we grew or maintained market share in approximately 60 % of the 80 key cohorts that we track .", "our plans call for total sales growth of 4 % to 6 % in 2021 , and that includes 2 points from the softex acquisition and a 1 to 2 point benefit from currencies .", "we expect to grow organic sales 1 % to 2 % .", "on the bottom line , we 're targeting adjusted earnings per share of $ 7.75 to $ 8 .", "that 's even to up 3 % year - on - year .", "so on that basis , using the midpoint of our 2021 outlook , we 're projecting to grow organic sales approximately 4 % and to increase adjusted earnings per share 7 % on average over that two - year period ."], "summary_gold": "net sales in 2021 are expected to increase 4 to 6 percent .<q>adjusted earnings per share in 2021 are expected to be $ 7.75 to $ 8.00 .<q>qtrly personal care segment sales of $ 2.3 billion rose 5 % .<q>kimberly - clark - authorized new $ 5 billion share repurchase program which supplements current $ 5 billion authorization expected to be completed later in 2021 .", "summary_pred": "organic sales were up 13 % in consumer tissue and down 7 % in k - c professional .<q>adjusted gross profit increased 10 % .<q>we expect to grow organic sales 1 % to 2 % .<q>on capital allocation , dividends and share repurchases totaled $ 2.15 billion .<q>our plans call for total sales growth of 4 % to 6 % in 2021 , and that includes 2 points from the softex acquisition and a 1 to 2 point benefit from currencies .<q>on the bottom line , we 're targeting adjusted earnings per share of $ 7.75 to $ 8 .<q>importantly , we grew or maintained market share in approximately 60 % of the 80 key cohorts that we track .<q>that 's the 10th consecutive year we 've returned at least $ 2 billion to shareholders .<q>that 's even to up 3 % year - on - year .<q>we generated $ 575 million of cost savings from our force and restructuring programs .<q>our october guidance was for earnings of $ 7.50 to $ 7.65 .<q>we 're about 85 % to 90 % through the total pre-tax charges , which we 've increased somewhat to reflect delays as a result of covid - 19 and costs for additional savings opportunities .<q>in terms of company profitability for 2021 , the midpoint of our planning assumptions implies a 70 basis point decline in adjusted operating margin .<q>volumes were up 4 % , and net selling prices and product mix each increased 1 % .<q>that was driven by advertising , which was up 90 basis points .<q>capital spending was $ 1.2 billion in 2020 , in line with plan and the prior year .", "len_article": 35, "len_summary_gold": 4, "len_summary_pred": 16, "len_sent_scores": 35}